These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 30520251

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB, Churg AM, Cheung S, Dacic S.
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [Abstract] [Full Text] [Related]

  • 5. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
    Cozzi I, Oprescu FA, Rullo E, Ascoli V.
    Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S, Özogul E, Koksal D, Sarinc Ulasli S, Firat P, Emri S.
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
    Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G, Murer B, Barbareschi M, Giuliani S, Cavazza A, Marchetti G, Vermi W, Facchetti F.
    Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455
    [Abstract] [Full Text] [Related]

  • 11. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z, Kepenekian V, Fenouil T, Glehen O, Villeneuve L, Isaac S, Hommell-Fontaine J, Benzerdjeb N.
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [Abstract] [Full Text] [Related]

  • 12. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
    Aydogdu G, Özekinci S.
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
    [Abstract] [Full Text] [Related]

  • 13. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M, Monaco SE, Jerome JA, Galateau-Salle F, Churg A, Dacic S.
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [Abstract] [Full Text] [Related]

  • 14. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
    Walts AE, Hiroshima K, McGregor SM, Wu D, Husain AN, Marchevsky AM.
    Diagn Cytopathol; 2016 Jul; 44(7):599-606. PubMed ID: 27121152
    [Abstract] [Full Text] [Related]

  • 15. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
    Carbone M, Shimizu D, Napolitano A, Tanji M, Pass HI, Yang H, Pastorino S.
    Oncotarget; 2016 Sep 13; 7(37):59314-59321. PubMed ID: 27447750
    [Abstract] [Full Text] [Related]

  • 16. [BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
    Jaouen A, Thivolet-Bejui F, Chalabreysse L, Piaton E, Traverse-Glehen A, Isaac S, Decaussin-Petrucci M, Depaepe L, Fontaine J, Remy I, Maury JM, Brevet M.
    Ann Pathol; 2016 Apr 13; 36(2):111-9. PubMed ID: 26995100
    [Abstract] [Full Text] [Related]

  • 17. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M, Kinoshita Y, Hamasaki M, Matsumoto S, Hida T, Oda Y, Iwasaki A, Nabeshima K.
    Lung Cancer; 2019 Apr 13; 130():187-193. PubMed ID: 30885343
    [Abstract] [Full Text] [Related]

  • 18. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM, McElherne J, Minor A, Keller-Ramey J, Dunning R, Husain AN, Vigneswaran W, Fitzpatrick C, Krausz T.
    Hum Pathol; 2017 Feb 13; 60():86-94. PubMed ID: 27771374
    [Abstract] [Full Text] [Related]

  • 19. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
    Pillappa R, Maleszewski JJ, Sukov WR, Bedroske PP, Greipp PT, Boland JM, Yi ES, Peikert T, Aubry MC, Roden AC.
    Am J Surg Pathol; 2018 Feb 13; 42(2):256-263. PubMed ID: 29076876
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology.
    Louw A, Lee YCG, Acott N, Creaney J, van Vliet C, Chai SM.
    Cytopathology; 2022 Jan 13; 33(1):84-92. PubMed ID: 34033161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.